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thRombosis and thromboembolism (WAYFARER Study)
Introduction Coronaviral pneumonia is accompanied not only with severe pulmonary lesions but also with 
systemic autoimmune inflammation, rapid activation of cytokines and chemokines, i.e., a cytokine 
storm, as well as a high risk of thrombosis and thromboembolism. Since there is no specific therapy 
for this new coronavirus infection (COVID-19), an effective and safe anti-inflammatory treatment 
is needed.
Material and Methods The efficacy and safety of high-dose pulse glucocorticosteroid (GC) therapy with methylprednisolone 
1000 mg for 3 days and dexamethasone 8 mg for another 3–5 days was investigated in 17 patients 
with severe coronavirus pneumonia using retrospective comparison analysis (control group, n=17). 
The primary endpoint of the study was the cumulative changes of the patient’s condition according 
to the original SHOKS-COVID score, including changes in the levels of C-reactive protein (CRP) 
(an inflammation marker), D-dimer (a thrombosis marker), computed tomography (CT) analysis 
of pulmonary involvement, and, in addition, an assessment of the clinical status. Treated and control 
patients had signs of pulmonary involvement (53.2 % and 25.6 %), increases in CRP levels (27- and 
19-fold), and more than two-fold increases in D-dimer levels (to 1.41 μg / ml and 1.15 μg / ml). In the 
GC treatment group, the status of these variables was more severe at baseline.
Results Pulse GC therapy proved effective and significantly reduced the SHOKS-COVID scores. The median 
difference was – 5.00 versus the control group (p=0.011). Shortness of breath, oxygen saturation, and 
the clinical status News-2 score were significantly reduced. In the GC group, CRP levels decreased 
significantly from 134 mg / dl to 41.8 mg / dl (p=0.009); however, D-dimer levels increased significantly 
from 1.41 μg / ml to 1.98 μg / ml (p=0.044). Corresponding changes were insignificant in the control 
group. Changes in the CT findings of pulmonary involvement were more beneficial in the treatment 
group, but this differences did not reach statistical significance (p=0.062). The high neutrophil counts 
(p=0.0001) increased even more and, with the persistently low lymphocyte counts, the neutrophil-
lymphocyte ratio (NLR), a marker of chronic inflammation, increased 2.5-fold (p=0.006) after the 
administration of GCs. Changes of the NLR and the D-dimer levels were correlated in the pulse GC 
therapy group, which emphasizes the association of chronic autoimmune inflammation and thrombosis 
in COVID-19 (r=0.49, p=0.04). There were no significant changes in the control group. Four patients 
developed venous thromboembolic complications (pulmonary embolism in two cases) after the 
pulse GC therapy despite concomitant anticoagulants in therapeutic doses. Recovery in the hormone 
treatment group was slower, with median duration of hospitalization of 26 days versus 18 days for the 
control group, p=0.001).
Conclusion High-dose pulse GC therapy has a rapid anti-inflammatory effect; however, it increases the NLR and 
the D-dimer levels, which increase the risk of venous thromboembolism.
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The new coronavirus disease caused by the SARS-CoV-2 virus, named COVID-19, was confirmed as 
a pandemic by the World Health Organization (WHO) 
on 11 March 2020. In severe cases of COVID-19, viral 
pneumonia develops with severe damage to small lung 
vessels, bronchioles, and alveoli.
Progressive systemic inflammation accompanied 
by low lymphocyte and high neutrophil counts plays 
a significant role in the COVID-19 pathogenesis. 
Pathological hyper-reactivity of the immune system, 
which results in uncontrolled activation of immune 
cells by cytokines in the sites of inflammation, and in 
the augmented release of cytokines and chemokines by 
immune cells, is called a cytokine storm. COVID-19 
patients demonstrate high levels of interleukins (IL) 
(IL-1 β, IL-1RA, IL-6, IL-8, IL-9, IL-10, IL-17), 
macrophage inflammatory protein, vascular endothelial 
growth factor, tumor necrosis factor-alpha (TNF-α), and 
other pro-inflammatory chemokines, cytokines, and 
signaling proteins. The cytokine storm increases the risk 
of developing acute respiratory distress syndrome and 
can cause multiple organ failure [1].
Glucocorticosteroids (GCs) are one of the most com-
mon anti-inflammatory agents with a long history of use. 
Currently, the WHO does not recommend routine use of 
corticosteroids in patients with viral pneumonia or acute 
respiratory distress syndrome, unless the patients have 
other conditions, such as asthma, acute exacerbation of 
chronic obstructive pulmonary disease, or septic shock 
[2]. The Interim Guidelines of the Ministry of Health of 
the Russian Federation mention the possibility of using 
GCs in low doses (methylprednisolone 1 mg / kg / day, 
intravenously) as a preventive anti-inflammatory therapy. 
However, pulse GC therapy is not included in the list 
of tactics for treatment of COVID-19 recommended 
by the Ministry of Health in the Interim Guidelines 
for the Prevention, Diagnosis, and Treatment of New 
Coronavirus Disease (COVID-19), 7th revision [3].
However, GCs, due to their high availability, are often 
used in the treatment of the inflammation and cytokine 
storm caused by the SARS-CoV-2 virus. A systematic 
review of 41 studies of 25 protocols for treatment of 
COVID-19 found that corticosteroid therapy was 
commonly used in different doses and regimens [4]. 
Unfortunately, GCs have many side effects. Some of 
the major medium-and long-term adverse effects of 
this group of agents are increased insulin resistance [5–
7], increased cardiovascular risk, and risk of bacterial 
infections [8]. Glucose metabolism disorders and 
increased risk of superinfections can be corrected in the 
setting of inpatient treatment of coronavirus pneumonia. 
The most dangerous side effect is an increased risk of 
thrombotic and thromboembolic complications, which 
are already characteristic of COVID-19, and which may 
cause multiple organ failure and worsen the prognosis. 
Several studies have shown that COVID-19 can be 
accompanied by hypercoagulation with inhibition 
of fibrinolysis. This leads to microthrombosis in the 
lung, kidney, and heart vessels, and an increased risk of 
venous thromboembolism (VTE), including pulmonary 
embolism (PE), arterial thromboembolism, and stroke 
[9, 10]. Moreover, an increased level of D-dimer, a fibrin 
degradation product used as a marker of increased risk 
of thrombosis, is an independent factor determining 
the poor prognosis of patients with COVID-19 [10, 
11]. Anticoagulant therapy becomes more common 
as knowledge accumulates and as understanding of 
the pathogenesis of the coronavirus disease improves 
[11]. GC treatment may potentially reduce the efficacy 
of  preventive treatment with low-molecular-weight 
heparin (LMWH) due to an increased risk of thrombosis.
The study of the efficacy i.e., possible suppression 
of  inflammation and cytokine storm and the safety, i.e., 
possible progression of cardiovascular complications 
and thrombosis, of glucocorticoid therapy in patients 
with COVID-19 is of scientific interest and practical 
significance.
We performed a retrospective cohort comparative 
study of 34 patients with severe coronavirus pneumonia 
who required anti-inflammatory treatment. The 
objective of the study was to evaluate the clinical efficacy 
and safety of high-dose pulse GC therapy (a three-day 
course with a one-week maintenance) in patients with 
COVID-19.
Material and methods
The study included 34 patients with a proven 
diagnosis of coronavirus pneumonia who were admitted 
to the Medical Research and Educational Center of 
Lomonosov Moscow State University (Lomonosov 
University Clinic). In all the cases, the diagnosis was 
confirmed by determining the presence of SARS-CoV-2 
virus RNA with polymerase chain reaction and typical 
computed tomography (CT) findings in the lung tissue. 
Initially, standard treatment with hydroxychloroquine 
and azithromycin was administered, with bromhexine 
and spironolactone added later. Moreover, all patients 
were treated with the anticoagulant LMWH, with the 
dose of LMWH calculated according to body weight. 
The patients were treated with LMWH from the first day 
of hospitalization and, in case of an increase in the levels 
of D-dimer ≥5 μg / ml, they were given therapeutic doses. 
If necessary, antibacterial therapy was adjusted. Patients 
in both groups took a mean of 1.4 antibiotic agents.
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There were no differences in both auxiliary 
thera py and in ordering agents for the treatment of 
comorbidities between the groups. Patients who 
required emergency anti-inflammatory therapy due 
to high fever, low blood oxygen saturation, elevated 
C-reactive protein (CRP), and the absence of changes 
in the CT scans were included in the GC treatment 
group (n=17). In the absence of anti-interleukin agents, 
it was decided to perform pulse treatment with high 
doses GCs: methylprednisolone 1000 mg intravenously 
for 3 days with subsequent dexamethasone 4 mg twice 
a day for 3–7 days. One patient additionally received 
tocilizumab 400 mg. Five patients received colchicine 
0.5 mg / day after the end of corticosteroid therapy. 
The control group comprised 17 patients with similar 
basic characteristics who were also treated in the 
Lomonosov University Clinic using the same protocols, 
but who did not receive pulse GC therapy. One patient 
received tocilizumab 400 mg. Only six of them were 
treated with colchicine 1 mg on the first day and 0.5 
mg / day afterward. No other specific anti-inflammatory 
therapy was performed in either group. The duration of 
observation was 10 days for both groups: 10 days from 
the start of treatment in the GC treatment group, and 
10 days from the time of inclusion in the control group. 
Analysis of data from the GC treatment and control 
groups was performed using double-blind endpoints for 
data sampling and statistical processing stages, which 
eliminated influence of the subjective factor on the 
findings.
The baseline characteristics of patients are given in 
Table 1. In the pulse GC therapy group, the median age 
was 59 years, and 15 of the 17 (88.2 %) patients were 
male with a median body mass index of 29.9 kg / m2. In 
the control group, the median age was higher, 68 years. 
This group included more male patients (58.5 %) with a 
mean body mass index of 27.8 kg / m2, but no differences 
were statistically significant. The groups did not differ 
in the number and prevalence of concomitant diseases, 
including cardiovascular disease with predominant 
hypertension, diabetes mellitus, chronic obstructive 
pulmonary disease, and cancer.
In the pulse GC therapy group, patients had 
significantly more severe fever than those in the control 
group (median difference was 0.9°C), more severe, but 
not statistically significant, severe shortness of breath 
(median respiratory rate (RR) 24 vs. 19 breaths per 
minute), which was associated with lower oxygen 
saturation (median levels 85 % vs. 94 % in room air and 
92 % vs. 96 % with oxygen therapy). All patients in the 
GC treatment group received oxygen therapy versus 
53 % in the control group (p=0.002). They were more 
likely to have been transferred to the intensive care unit 
(ICU) and to have received assisted ventilation (AV), 
although there were no significant differences in these 
parameters between the groups. The groups did not 
differ significantly in baseline systolic blood pressure 
(SBP). Tachycardia was observed in the group of more 
severely ill patients who received pulse GC therapy.
Both groups had characteristics of severe coronavirus 
pneumonia and did not differ in most parameters of 
the biochemical profile. The cumulative indicator of 
inflammation severity (C-reactive protein [CRP]) 
was 19-time higher than normal in the control group 
and 27-times higher than normal in the GC treatment 
group (p=0.048). The levels of D-dimer were increased 
three-fold in the GC treatment group compared to the 
control group, which reflected an increased tendency for 
thrombosis during the inflammatory process along with 
elevated levels of fibrinogen (p=0.125). Both groups 
demonstrated low lymphocyte and high neutrophil 
counts which exceeded normal values only in the GC 
treatment group. The neutrophil-lymphocyte ratio 
(NLR) was 4.06 in the control group and 6.05 in the 
GC treatment group (p=0.125). Platelet count, glucose, 
creatinine, and estimated glomerular filtration rate 
(GFR) were within normal limits and did not differ 
between the groups.
Lung and chest computed tomography (CT) scans 
were produced using a 32 slice SOMATOM Scope CT 
scanner (Siemens, Germany). The scans were obtained 
with 1-mm slices. During the first examination, the 
standard CT protocol (tube voltage 120 kV, automatic 
tube current modulation 200–400 mA) was used. The 
following investigations were carried out using a low-
dose CT protocol with reduced tube voltage (100 or 
110 kV) and automatic tube current modulation (40–
120 mA). The mean radiation exposure was 3.9±0.4 
mSv under the standard protocol and 0.9±0.2 mSv 
under the low-dose protocol. CT scans were performed 
at admission and discharge and were repeated during 
hospitalization as deemed clinically necessary, but at 
least once every 5 days. All the scans were stored in 
DICOM format in the radiological information network 
(PACS / RIS) of the Medical Research and Educational 
Center of Lomonosov Moscow State University. The 
CT scans were processed and analyzed in Syngo.via 
(Siemens) workstations. A semi-quantitative score for 
assessing the amount of infiltration and consolidation 
areas of the lung tissue was used to process and interpret 
CT findings, as recommended by the Interim Guidelines 
of the Russian Ministry of Health «Prevention, 
Diagnosis and Treatment of New Coronavirus Disease 
(COVID-19) 6 and 7 versions (CT1–CT4).
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The Russian software complex Gamma Multivox was 
used for an accurate quantitative analysis of the changes in 
the volume of alterations of the lung parenchyma caused 
by COVID-19 in all cases, with a special application for 
analyzing COVID-19 lung tissue lesions. This software 
was created by the laboratory of medical computer 
systems of D. V.  Skobeltsyn Moscow State University 
and the Faculty of Fundamental Medicine (FFM) of 
the Lomonosov Moscow State University (https://
multivox.ru), and was used for the analysis of all the CT 
scans of each subject. This included automatic color-
coding and calculation of the amount of ground-glass 
opacities and consolidations on CT images, estimation 
of the volume in cubic centimeters and as a percentage 
relative to the lung volume. The sum of any ground-glass 
opacities and consolidation areas was taken into account. 
The program generated a table with measured values, 
and new data was added to the table as examinations 
were performed. Laboratory tests included 1) blood 
biochemical profile (CRP, creatinine, urea, glucose) 
Table 1. Baseline patient characteristics
Parameters
Pulse GC  
therapy group*,  
n=17
Control  
group,  
n=17
p n
General characteristics
Age, years, median [25%; 75%] 59.0 [52.0; 67.0] 68.0 [46.0; 81.0] 0.309 34
Male, n (%) 15 (88.2%) 10 (58.8%) 0.125 34
Hypertension, n (%) 12 (70.6%) 9 (52.9%) 0.480 34
BMI, kg/m2, median [25%; 75%] 29.9 [27.0; 32.4] 27.8 [27.0; 31.8] 0.607 31
CAD, n (%) 2 (11.8%) 2 (11.8%) 1.000 34
Diabetes mellitus, n (%) 2 (11.8%) 1 (5.88%) 1.000 34
COPD, bronchial asthma, n (%) 1 (5.88%) 2 (11.8%) 1.000 34
Cancers, n (%) 1 (5.88%) 1 (5.88%) 1.000 34
Clinical characteristics
Body temperature, °C, median [25%; 75%] 37.8 [37.2; 38.1] 36.9 [36.6; 37.1] 0.006 34
RR, breaths per min, median [25%; 75%] 24.0 [19.0; 26.0] 19.0 [18.0; 22.0] 0.069 34
HR, bpm, median [25%; 75%] 97.0 [82.0; 104] 78.0 [70.0; 88.0] 0.016 34
SBP, mm Hg, median [25%; 75%] 123 [120; 130] 120 [115; 130] 0.690 34
SpO2 room air, %, median [25%; 75%] 85.0 [80.0; 89.0] 94.0 [93.5; 96.0] <0.001 32
SpO2 oxygen support,%, median [25%; 75%] 92.0 [90.0; 93.0] 96.0 [96.0; 98.0] 0.006 26
Any oxygen support, n (%) 17 (100%) 9 (52.9%) 0.002 34
ICU, n (%) 12 (70.6%) 6 (35.3%) 0.084 34
AV, n (%) 6 (35.3%) 1 (5.88%) 0.085 34
Biochemical characteristics
CRP, mg/dL 134 [112; 194] 95.1 [67.0; 134] 0.048 34
D-dimer, μg/ml 1.41 [1.20; 1.96] 1.15 [1.00; 1.36] 0.125 34
Fibrinogen, g/l 6.83 [5.84; 7.32] 5.93 [5.48; 7.29] 0.318 32
Lymphocytes, 109/l 0.66 [0.48; 1.29] 1.05 [0.89; 1.14] 0.221 34
Neutrophils, 109/l 5.02 [3.06; 6.38] 4.23 [3.00; 6.33] 0.617 34
Neutrophil/lymphocyte ratio 6.05 [3.80; 11.2] 4.06 [2.12; 5.45] 0.125 34
Platelets, 109/l 216 [179; 248] 196 [158; 264] 0.642 34
Glucose, mmol/l 6.06 [5.10; 7.60] 6.05 [5.78; 6.49] 0.547 34
Creatinine, μmol/l 91.0 [86.0; 102] 82.0 [64.0; 105] 0.438 34
GFR, ml/min/1.73 m2 (CKD-EPI) 78.0 [63.0; 87.0] 76.0 [65.0; 98.0] 0.783 34
Lung lesion*
CT stage 3.00 [2.00; 3.00] 2.00 [1.00; 2.00] <0.001 34
CT 3–4, n (%) 10 (58.8%) 0 (0.00%) <0.001 34
CT lesion (%) 53.2 [37.3; 65.1] 25.6 [12.6; 34.7] <0.001 33
Cumulative risk
NEWS-2 score 11.0 [6.00; 12.0] 5.00 [4.00; 5.50] <0.001 32
SHOKS-COVID score 13.0 [11.0; 15.0] 7.00 [6.00; 9.00] <0.001 34
*, before the start of pulse therapy. **, the median stage of cumulative pulmonary involvement according to the CT findings  
under the Guidelines of the Russian Ministry of Health and the Moscow Health Department. CRP, C-reactive protein; GFR,  
glomerular filtration rate; CT, computed tomography. The quantitative data are expressed as the median and interquartile range.
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performed on an automatic biochemical analyzer AU480 
Beckman Coulter, Germany, 2)  complete blood count 
(5  diff ) performed on a hematological analyzer XN 
2000 Sysmex Corporation, Japan, 3) hemostasis analysis 
(fibrinogen, D-dimer) performed on an automatic 
hemostasis analyzer STA-Compact Diagnostics Stago 
SAS, France.
According to the CT findings, all 34 patients had 
signs of bilateral viral pneumonia typical for COVID-19 
disease. According to the classification recommended by 
the Russian Ministry of Health and the Moscow Health 
Department [3], the median of stages was 2.0 in the 
control group and 3.0 in the GC treatment group. In the 
GC treatment group, 58.8 % of patients had stage 3–4 
pulmonary involvement, but there were no such patients 
in the control group. The computer analysis (MultiVox, 
FFM MSU) found that the cumulative volume of 
pulmonary involvement (ground-glass opacity, crazy-
paving pattern, areas of consolidation and fibrosis) 
was 25.6 % in the control group and 53.2 % in the GC 
treatment group (p<0.001).
We used two scores to objectify the severity of the 
clinical condition and to adequately assess the effects of 
the therapy:
1) the NEWS-2 score (National Early Warning Score 
(NEWS) 2, Standardizing the assessment of acute-
illness severity in the NHS. Updated report of a working 
party. London: RCP, 2017), modified for patients with 
COVID-19 [12],
2) the SHOKS-COVID score, our original clinical 
assessment scale for patients with coronavirus disease.
The NEWS-2 score was designed to assess the severity 
of the condition of patients with acute respiratory 
syndromes. It has been widely used for many years to 
evaluate the risk of clinical deterioration, for timely and 
competent decision-making on the manner of treatment, 
and for the need for treatment intensification. This 
score has been validated in several populations, and it 
has been used for rapidly assessing the risk of clinical 
deterioration and for triage of patients with COVID-19. 
It is based on common clinical manifestations: RR, 
oxygen saturation, the need for assisted ventilation, state 
of consciousness, body temperature, as well as heart rate 
(HR) and SBP. However, it does not sufficiently take into 
account the characteristics of patients with COVID-19. 
Chinese researchers supplemented this score with an age 
parameter and added the maximum number of points (3) 
for age of over 65 years [12]. That modification reflected 
an early understanding of the course of COVID-19 
during the outbreak in Wuhan. It is evident now that age 
is not the only aggravating factor. Concomitant diseases 
also worsen the prognosis. The maximum risk of death 
is observed in the subgroup of patients over 80 years 
old, in which this risk is 6 times higher than in patients 
aged 65 [13]. According to the modified NEWS-2 score, 
low risk of poor prognosis is indicated by score 0, mild 
risk by 1–4, high risk by 5–6, and very high risk by 7 
or more. The median NEWS-2 score in patients of the 
control group was 5, corresponding to high risk, and in 
patients of the GC treatment group, this score was 11, 
corresponding to very high risk.
Assessment of the condition of patients with 
COVID-19 depends on several key parameters, not only 
the severity of shortness of breath, oxygen saturation, and 
the need for lung ventilation. These parameters further 
characterize the severity of pulmonary involvement and 
respiratory failure. The state of consciousness is directly 
correlated with the patient’s admission to the ICU 
and predominantly with receiving AV. The amount of 
damage to the lung tissue according to the CT findings is 
one of the key parameters, which is not always correlated 
with clinical manifestations of shortness of breath, as 
well as the severity of the inflammatory process, the 
main markers of which are the severity of fever and 
the level of CRP. Moreover, the risk of thrombotic and 
thromboembolic complications that accompany damage 
of the lung tissue, which is determined by the level of 
the D-dimer, can be used as one of the main prognostic 
factors indicating an adverse course of the disease.
Based on the successful experience of developing 
an integral clinical assessment score (SHOKS) for 
patients with chronic heart failure (Yu. N. Belenkov and 
V. Yu. Mareev, 2000), we developed our original score to 
determine the clinical status of patients with COVID-19 
by taking into account the main markers of the disease 
severity, (SHOKS  – COVID, see Table 2). The score 
0 to 3 corresponds to low risk, 4–6 to medium risk, 7–10 
to serious risk (i.e., above average), 11–14 to high risk, 
and finally, the score of 15 or higher to extremely high 
risk of an unfavorable course of the disease, with rapid 
progression of pulmonary involvement, multiple organ 
failure, conditions which are extremely difficult to treat. 
This score was based on theoretical assumptions but not 
on data from any cohort analysis nor the definition of 
risk groups and has not yet been validated.
The median SHOKS-COVID score was 7.0 for 
patients of the control group, which corresponds to 
above-mean risk, and 12.0 for patients who received 
pulse GC therapy, which indicates high risk. As we can 
see, the condition of patients in both groups was rated as 
much more severe according to the NEWS-2 score than 
by the SHOKS-COVID score. However, distinguishing 
between the high and very high risk is always mostly a 
philosophical question.
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The decision to conduct more active anti-inflam-
matory treatment with GCs in the GC treatment group 
was mainly determined by the identified differences in 
the clinical course of the disease. The primary endpoint 
of the study was the change in the SHOKS-COVID 
score. The secondary endpoints were the changes in the 
clinical score (NEWS-2) and oxygen saturation (SpO2), 
changes in the blood levels of CRP and D-dimer, and 
estimation of the degree of pulmonary involvement on 
CT scans in Multivox.
Statistical Analysis
Quantitative data are expressed as the median 
and interquartile range (Me and 25 %;75 %), whereas 
qualitative data are presented as absolute and relative 
values. The significance of intergroup differences in 
qualitative characteristics was assessed using the χ2 
test and two-way Fischer’s exact test. The quantitative 
data were compared between groups using the Mann-
Whitney U-test. To compare intragroup changes of 
parameters, the Wilcoxon signed-rank test was used for 
related samples with quantitative data, and McNemar’s 
test was used for qualitative data.
A logarithmic data transformation was performed, 
followed by the calculation of the Pearson correlation 
coefficient to assess correlations of parameters with 
nonparametric distributions. The threshold for statis-
tical significance was p<0.05. Statistical analyses were 
performed using the R programming language in the 
R Studio.
Results
The changes in the SHOKS-COVID scores as the 
primary endpoint are shown in Figure 1. The median 
SHOKS-COVID score increased insignificantly from 
7.00 [6.00; 9.00] to 9.00 [5.50; 10.0] (p=0.148) in the 
control group and remained in the same risk category, 
i.e., above average. It decreased from 13.0 [11.0; 15.0] 
to 10.0 [7.0; 13.0] (p=0.01) in the pulse GC therapy 
group. After treatment values differed significantly, 
+1.00 [–2.25; +3.00] in the control group and  – 4.00 
[–5.00;  –2.00;] in the pulse GC therapy group 
(p=0.011).
Figure 2 shows the changes in the clinical condition 
as measured by the NEWS-2 score. In the control 
group, the score decreased insignificantly from 5.00 
[4.00; 5.50] to 3.00 [3.00; 6.50] (p=0.97). In the 
GC treatment group, this decrease from 11.0 [6.00; 
12.0] to 6.00 [3.75; 9.25] was significant (p=0.026). 
Both groups also significantly differed in the amount 
of decrease as measured by the NEWS-2 clinical 
score:  –1.00 [–2.00; +2.50] vs.  –3.50 [–4.50;  –0.75] 
in  the control and pulse GC therapy groups, 
respectively (p=0.043).
The maximum difference in the change of the patients’ 
well-being was due to changes in oxygen saturation and 
reduced shortness of breath (Figure 3). This parameter 
did not change in the control group: 94.0 [93.5; 96.0] 
% at baseline and 94.0 [89.5; 97.0] % after treatment 
(p=0.51). Oxygen saturation increased significantly 
in the pulse therapy group from 85.0 [80.0; 89.0] % to 
93.0 [91.5; 95.0] % (p=0.025). In the GC treatment 
group, the changes of this parameters were clearly more 
significant: +8.00 [+2.25; +13.0] % vs. +1.00 [  –6.00; 
+4.00] % in the control group (p=0.008).
Other changes in clinical parameters are provided in 
Table 3. As shown in the table, patients in the pulse GC 
Table 2. Clinical Assessment Score  
for Patients with COVID-19 (SHOKS-COVID) 
based on Mareev modification 2020
Parameter Value Score
1) RR at rest
<18 0
18–22 1
23–26 2
>26 (or AV) 3
2) Body temperature
35.5–37⁰C 0
37.1–38.5⁰C 1
>38.5⁰C 2
3) SpO2
>93% 0
90–92.9% 1
<90% 2
4) Ventilation
Not needed 0
Low-flow ventilation in 
room air 1
Non-invasive lung 
ventilation in the ICU 2
Invasive assisted 
ventilation in the ICU 3
5) CRB, mg/dl
<10 0
10–60 1
60–120 2
>120 3
6) D-dimer, μg/ml
<0.5 0
0.51–2.00 1
2.01–5.00 2
>5.00 3
7) CT lung lesion based 
on computer analysis (%)
No pneumonia 0
0–24% 1
25–49% 2
50–74% 3
75–100% 4
TOTAL MAXIMUM 20
RR, respiratory rate; SpO2, oxygen saturation; CRP,  
C-reactive protein; GFR, glomerular filtration rate; CT, computed 
tomography; AV, assisted ventilation; ICU, intensive care unit
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therapy group had a statistically significant decrease in 
body temperature to normal values, reductions of RR by 
5 breaths per minute and in heart rate by 13 bpm. The 
number of patients in the ICU decreased from 12 to 8; 
one of them was transferred from AV to non-invasive 
lung ventilation, and the number of patients in clear 
consciousness increased from 8 to 11. No significant 
changes occurred in the control group, which once again 
characterizes coronavirus pneumonia as a very persistent 
disease that is barely treatable at the stage of an extensive 
inflammatory process in the lung tissue.
Figure 4 shows the results of computer processing 
of  the chest CT scans with determination of the 
cumulative percentage of pulmonary involvement at the 
time of inclusion and on Day 10 of observation. The 
sum of any ground-glass opacities and consolidation 
areas was taken into account. Despite the treatment, 
the cumulative volume of pulmonary involvement 
unexpectedly increased significantly from 25.6 
[12.6; 34.7] % to 44.9 [23.3; 52.2]  % (p=0.0026) in 
the control group. Taking into account the absence 
of changes in oxygen saturation and shortness of breath, 
it is possible that, with a higher degree of involvement, 
non-ventilated areas of the lungs (consolidations) 
could turn into partially ventilated areas (ground-
glass opacities). The stage analysis, according to the 
Guidelines of the Russian Ministry of Health, showed 
no clinical meaningful changes in the data: the median 
was 2.00 [1.00; 2.00] at baseline and 2.00 [2.00; 3.00] 
at the end of the observation, although this difference 
was statistically significant (p=0.0147). The degree of 
pulmonary involvement according to the computer 
analysis did not change in the GC treatment group: 53.2 
[37.3; 65.1] % at baseline and 53.9 [41.3; 68.4] % after 
the GC treatment (p=0.67). The stage of pulmonary 
Table 3. Changes in the clinical status of patients before and after treatment
Parameters
Hormone therapy (n = 17)
р
Control group (n = 17)
р
Baseline In 10 days Baseline In 10 days
Body temperature, ⁰С 37.8 [37.2; 38.1] 36.6 [36.2; 37.0] 0.004 36.9 [36.6; 37.1] 36.6 [36.3; 36.9] 0.109
RR, breaths per min 24.0 [19.0; 26.0] 19.0 [16.0; 22.0] 0.117 19.0 [18.0; 22.0] 19.0 [18.0; 20.0] 0.291
HR, bpm 97.0 [82.0; 104] 84.0 [76.0; 88.0] 0.092 78.0 [70.0; 88.0] 80.0 [73.0; 86.0] 0.343
SBP, mm Hg 123 [120; 130] 120 [115; 130] 0.67 120 [115; 130] 118 [110; 122] 0.075
SpO2, room air, % 85.0 [80.0; 89.0] 93.0 [91.5; 95.0] 0.025 94.0 [93.5; 96.0] 94.0 [89.5; 97.0] 0.512
SpO2, vent., % 92.0 [90.0; 93.0] 96.0 [91.8; 98.0] 0.261 96.0 [96.0; 98.0] 96.0 [92.5; 97.5] 0.752
Any O2 support, n (%) 17 (100%) 13 (76.5%) 0.133 9 (52.9%) 11 (64.7%) 0.683
ICU, n (%) 12 (70.6%) 8 (47.1%) 0.288 6 (35.3%) 4 (23.5%) 0.683
AV, n (%) 6 (35.3%) 5 (29.4%) 0.133 1 (5.88%) 2 (11.8%) 1
Alteration  
of consciousness, n (%) 9 (52.9%) 6 (35.3%) 0.371 0 (0.00%) 3 (17.6%) 0.248
RR, respiratory rate; HR, heart rate; SBP, systolic blood pressure; SpO2, oxygen saturation;  
ICU, intensive care unit; AV, assisted ventilation. The quantitative data are expressed as the median and interquartile range.
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involvement also did not change: median values were 
3.00 [2.00; 3.00] before and after pulse GC therapy 
(p=0.82). We can also assume that a significant decrease 
in shortness of breath, an increase in oxygen saturation, 
and lower rates of oxygen support were associated more 
with qualitative, rather than quantitative, characteristics 
of pulmonary involvement. Anyway, the median change 
in the degree of pulmonary involvement according to CT 
findings was only + 0.75 [–10.95; +13.9] % in the pulse 
GC therapy group and +17.6 [+0.10; +23.6] % in the 
control group; these differences did not reach statistical 
significance (p=0.062).
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Figure 5. Computer quantitative processing of CT lung findings, patient I., 44 years old;  
explanations are given in the text. Figures 5.01: 22.04.2020; 5.02: 29.04.2020; 5.03: 10.05.2020
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We present a case report (Figure 5) of a 44-year-
old patient I, who was admitted to the Lomonosov 
University Clinic on 22 April 2020 (Day 2 of admitting 
patients with COVID-19), with moderate pulmonary 
involvement of 38.4 %, of which the minimum severity 
in the form of ground-glass opacities (light yellow) was 
17.1 %, high severity in the dense ground-glass opacities 
(brown) was 21.3 %, and consolidations (red) was 1.5 %.
The patient had had low-grade fever for three 
days (37.6°C), no severe shortness of breath (RR 
18 breaths per min), respiratory oxygen saturation 
94 %, CRP 38.6 mg / dL, D-dimer 0.89 μg / ml during 
administration of imidazolyl ethanamide pentandioic 
acid, hydroxychloroquine, and azithromycin which 
were prescribed before admission to the hospital. The 
patient’s status was reasonably good. Azithromycin was 
continued. Bromhexine was administered 8 mg x 4 times 
a day instead of hydroxychloroquine, spironolactone 
50 mg x 2 times a day, and enoxaparin sodium 40 mg x 
2 times a day. Similar therapy was used in the control 
group.
Until 28 April 2020, the patient’s status gradually 
worsened, antibiotic therapy was changed, and the 
dose of enoxaparin sodium was increased to 80 mg 
x 2 times a day. But on 29 April 2020, the condition 
deteriorated critically. Figure 5.02 shows the CT 
findings as of 29  April 2020. Pulmonary involvement 
increased to 68.6 % with only 6.6 % of ground-glass 
opacity, 21.1 % of  dense ground-glass opacity, and 
40.9 % of consolidation (severe lesion 62 %). The 
patient had a fever of 38.5 C, RR 26 breaths per 
min, HR 120 bpm, oxygen saturation 78 %, CRP 425 
mg / dL, D-dimer 1.33 μg / ml. Neutrophil counts were 
increased to 7.55x109 / l, and lymphocyte counts were 
decreased to 0.47x109 / l. The neutrophil-lymphocyte 
ratio (NLR) was 16.06. The patient was transferred 
to the ICU and put on AV. Given the severity of the 
disease, acute inflammation, and the absence of agents 
acting on interleukins, it was decided to perform pulse 
treatment with methylprednisolone 1000 mg for 3 days, 
followed by dexamethasone 8 mg x 2 times a day for 5 
more days. Then, the patient received colchicine 1 mg 
on the first day and 0.5 mg on the following days before 
discharge. As a result, CRP levels decreased 4-fold, 
fibrinogen levels from 11.07 to 7.2 g / l, SpO2 from 
78 % to 94 %, RR decreased to 20 breath per min, and 
HR to 92 bpm. The D-dimer increased insignificantly 
to 1.63  mg / ml. Neutrophil counts increased to 
17.2x109 / l, and lymphocyte counts increased to 
1.39x109 / l. The NLR decreased to 12.4. The degree of 
pulmonary involvement significantly decreased by Day 
10 after the start of pulse GC therapy (Figure 5.03) 
with an evident anti-inflammatory effect. Ground-glass 
opacity was moderate and consolidation lesions of the 
lung tissue was 12.3 %. The cumulative volume of the 
unaffected lung tissue increased to 75.4 %. The patient 
was extubated on Day 6 after the pulse GC therapy, 
transferred from the ICU on Day 10, and discharged 
from the hospital on Day  14 with recommendations 
to take colchicine 0.5 mg / day and rivaroxaban 10 
mg / day. The follow-up examination is scheduled on 
day 45.
Table 4 shows changes in the laboratory parameters 
in the GC treatment and control groups. Changes in 
the CRP levels, as the most common marker of the 
severity of the inflammatory process, were of the greatest 
interest. It decreased statistically significantly in the GC 
treatment group (p=0.009) and insignificantly in the 
control group. The median decrease was twice as large 
in the GC treatment group (–85.57 [–155.3;  –2.36] 
mg / dL) than in the control group (+41.03 [–65.0; 
+24.3] mg / dL), but the differences were not significant 
(p=0.109). However, the baseline levels of CRP were 
higher by 39 mg / dl in the GC treatment group, and after 
the treatment, on the contrary, the levels were higher in 
the control group by 15 mg / dl. The CRP levels decreased 
significantly (by more than 10 %) in 13 (76.5 %) patients 
in the GC treatment group and in 6 (35.3 %) patients in 
the control group.
D-dimer levels increased significantly in the GC 
treatment group (p=0.044), but they did not change 
in the control group (p=0.31). The median increase 
was + 0.66 [–0.11; +9.16] μg / ml (47 % of the baseline 
value) in the GC treatment group and +0.01 [–0.64; 
+0.47] μg / ml in the control group (p=0.040). An 
increase in the D-dimer levels by more than 10 % was 
observed in 12 (70.6 %) patients in the GC treatment 
group. Two patients experienced PE, and two more 
patients developed venous thrombosis of the extremities 
(4 / 17=23.5 %). In these cases, the D-dimer levels 
increased to 12.8 and 20.0 μg / ml in PE and to 13.5 and 
12.5 μg / ml in venous thrombosis, respectively. In the 
control group, no significant increases in the D-dimer 
levels and thrombotic complications were detected. 
Changes in fibrinogen levels were minimal in both 
groups.
A baseline decrease in lymphocyte counts was 
observed in both groups, mostly among patients who 
were treated with GCs. They did not significantly change 
by the end of observation in either group. Neutrophil 
counts barely changed and even tended to decrease 
in the control group. As is typical with GC treatment, 
neutrophil counts significantly increased by 73 % 
(p<0.0001)
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The NLR, which is an important parameter reflecting 
the severity of chronic inflammation, increased by 153 % 
in the GC treatment group (p=0.006) and decreased 
insignificantly in the control group. The median change 
was + 6.12 [–16.5; + 0.34] in the GC treatment group vs. 
–0.315 [–1.73; +5.17] in the control group (p=0.038). 
Among the other parameters, a significant increase in 
platelet counts in both groups is noteworthy, which is 
quite good considering the aggressive anticoagulant 
therapy.
Changes in glucose levels were oppositely directed: 
an insignificant increase in the GC treatment group 
(p=0.222) and a significant decrease in the control 
group (p=0.032). The median changes were –1.02 
[–1.63; –0.55] mmol / l in the control group and + 0.02 
[–1.13; +3.15] mmol / l in the GC treatment group. 
These differences were not significance (p=0.06). 
However, 7 of 17 (41.2 %) patients in the GC treatment 
group had increased glucose of more than 9 mmol / l, 
which required ordering / enhancing the hypoglycemic 
therapy. There were no such cases in the control group. 
No significant changes in kidney function, creatinine 
levels, and GFR were found in either group.
The mean time of inpatient treatment was 18.0 [16.0; 
20.5] days in the control group and 26.0 [22.0; 31.5] 
days in the GC treatment group (p=0.001).
We present a case report of a 62-year-old patient A. 
with COVID-19 and 68.2 % pulmonary involvement 
according to the CT findings (Figure 6). The patient 
was observed for a long period. The CRP levels were 
122 mg / dL, D-dimer 1.33 μg / ml, SpO2 89 % without 
oxygen therapy. Severely decreased lymphocyte 
counts (0.34x109 / l), increased neutrophil counts 
(6.26x109 / l), and an extremely high NLR (18.4) were 
noticeable as markers of severe inflammation and VTE 
risk. The patient was transferred to the ICU and put on 
Table 4. Changes in laboratory values in patients before and after treatment
Parameters
Hormone therapy (n=17)
p
Control group (n=17)
p
Baseline Changes Baseline Changes
CRP, mg/dL 134 [112; 194] 41.8 [22.6; 101] 0.009 95.1 [67.0; 134] 56.9 [9.48; 122] 0.306
D-dimer, μg/ml 1.41 [1.20; 1.96] 1.98 [1.63; 10.0] 0.044 1.15 [1.00; 1.36] 1.21 [0.73; 1.94] 0.860
Fibrinogen, g/l 6.83 [5.84; 7.32] 6.72 [4.82; 7.55] 0.322 5.93 [5.48; 7.29] 6.50 [6.25; 6.99] 0.742
Lymphocytes, 109/l 0.66 [0.48; 1.29] 0.70 [0.51; 0.95] 0.943 1.05 [0.89; 1.14] 1.24 [0.69; 1.63] 0.306
Neutrophils, 109/l 5.02 [3.06; 6.38] 8.68 [6.77; 14.4] 0.0001 4.23 [3.00; 6.33] 3.84 [3.40; 6.44] 0.781
NLR 6.05 [3.8; 11.2] 15.3 [6.62; 19.7] 0.006 4.06 [2.12; 5.45] 3.04 [2.12; 8.98] 0.890
Platelets, 109/l 216 [179; 248] 280 [229; 347] 0.001 196 [158; 264] 356 [311; 420] 0.0001
Glucose, mmol/l 6.06 [5.10; 7.60] 7.16 [5.47; 9.96] 0.222 6.05 [5.78; 6.49] 4.70 [4.33; 5.29] 0.032
Creatinine, μmol/l 91.0 [86.0; 102] 81.0 [67.5; 93.8] 0.088 82.0 [64.0; 105] 82.0 [72.0; 91.0] 0.477
GFR, ml/min/1.73 m2 78.0 [63.0; 87.0] 85.5 [80.5; 93.8] 0.088 76.0 [65.0; 98.0] 86.0 [67.0; 98.0] 0.448
CRP, C-reactive protein; GFR, glomerular filtration rate; CT, computed tomography.  
The quantitative data are expressed as the median and interquartile range.
e arrows show contrast defects in the branches of the right upper lobar artery.
A B
Figure 6. CT angiopulmonography (a – transverse plane, b – frontal plane)
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non-invasive lung ventilation. It was decided to conduct 
pulse GC therapy with high doses of GCs. After 5 days 
of the treatment, the patient’s condition improved, 
body temperature decreased to normal, CRP level 
decreased to 46 mg / dl, oxygen saturation increased 
to 95 %, and the degree of pulmonary involvement 
decreased to 38.2 %. The patient was transferred from 
the ICU. Although lymphocyte counts remained 
decreased (0.37x109 / l), the NLR increased to 20.6, and 
D-dimer increased to 2.74 μg / ml. The patient rapidly 
deteriorated the next day. Shortness of breath became 
extremely severe, chest pain occurred, and the D-dimer 
level increased to 13.52 μg / ml. CT angiography showed 
PE despite the continuous administration of LMWH 
in therapeutic doses. The dose of LMWH was further 
increased, and dipyridamole was added. Subsequently, 
all the complications were successfully reversed, and 
the patient was discharged from the hospital in good 
condition on Day 27.
Discussion
COVID-19 passes through several stages, each 
requiring specific treatment. At the onset of viral 
pneumonia with alveolar lesions, the problem becomes 
more severe because of the progression of systemic 
inflammation and the involvement of pulmonary 
parenchyma, bronchioles, and small vessels, as well as 
increased clotting. In these cases, hyper-reactivity of the 
immune system is accompanied by excessive activation 
of cytokines, further activation of  macrophages and 
epithelial cells, and a constant increase in the release 
of cytokines and chemokines, i.e., a cytokine storm 
[14, 15]. The objective of this study was to evaluate the 
treatment of this category of patients with COVID-19. 
The Guidelines of the WHO and the Russian Ministry 
of Health suggest using preventive anti-inflammatory 
therapy in such cases to arrest the cytokine storm 
and overcome critical inflammation [2, 3]. Given 
the significant role of  pro-inflammatory ILs, the IL-
6 inhibitor, tocilizumab [16], the IL-1β inhibitor, 
canakinumab [17], the IL-17 inhibitor, secukinumab 
[18], the JAK-1 and JAK-2 Janus-kinase inhibitors, 
ruxolitinib [19], are recommended as anti-inflammatory 
agents. Even with possible high efficacy of these agents, 
which is yet to be verified in clinical studies, their 
availability and cost leave much to be desired.
Although the most popular anti-inflammatory 
agents in the past 50 years, GCs are not recommended 
by the WHO in COVID-19, and only the 7th version 
of the Russian Ministry of Health Guidelines included 
the possible use of low doses of GCs (1 mg / kg / day). 
A meta-analysis of studies on the use of corticosteroids in 
coronavirus pneumonia, including COVID-19, showed 
no positive effect on prognosis and they slowed-down 
elimination of the virus [20, 21]. However, the early 
pulse therapy with high-dose GCs in atypical pneumonia 
decreased progression of the disease and improved 
resolution of alterations in the pulmonary structures with 
low risk of side effects [22, 23]. GC therapy is limited by 
its ability to enhance prothrombotic factors, especially 
in immune inflammation, which occurs in COVID-19 
with the cytokine storm [24]. Several studies associate 
the risk of VTE development during corticosteroid 
therapy with dose level, and the maximum increase in 
risk is observed with doses from 1000 to 2000 mg / day. 
[25]. The main danger of GC therapy is that the risk of 
thrombosis and thromboembolism occurs immediately 
after the start of treatment [26].
Given the ambiguities and insufficient knowledge 
regarding this issue, the objective of our study was to 
assess the balance of efficacy and safety of pulse GC 
therapy (intravenous methylprednisolone 1000 mg for 
3 days followed by dexamethasone mg for 3–7 days) 
for the treatment of patients with severe coronavirus 
pneumonia in comparison to the group of patients 
who did not receive the anti-inflammatory therapy. 
Examinations of patients showed signs of systemic 
inflammation with an extreme 19-fold increase in 
the CRP levels, a marker of the cytokine storm, in the 
control group and a 27-fold increase in the GC treatment 
group. Fever, low lymphocyte counts (0.66x109 / l), 
high neutrophil counts (5.02x109 / l), and increased 
NRL (6.05), a threefold increase in D-dimer levels, 
shortness of breath (RR 26 breaths per min) with SpO2 
(85 %), tachycardia (HR 97 bpm) were detected in the 
GC treatment group. The cumulative NEWS-2 clinical 
score, which includes treatment in the ICU (70.6 %) 
and AV (35.3 %), and confusion, as well as the clinical 
manifestations of the disease, was 11. A score of more 
than 7 corresponds to very high risk. The degree of 
pulmonary involvement was more than 50 %, which 
corresponded to stage 3, according to the Russian 
Ministry of Health Guidelines. The cumulative SHOKS-
COVID score, which includes the CRP and D-dimer 
levels and the volume of pulmonary tissue lesions, as 
well as clinical parameters, and takes into account 
the predictive factors, was 13 in patients in the GC 
treatment groups, which corresponded to a high risk of 
an unfavorable outcome Patients in the control group 
had a less severe course of the disease, according to most 
of the parameters examined. On one hand, that made it 
difficult to compare results in both groups, but on the 
other hand, it gave us hope for a more favorable course 
of the disease.
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The study confirmed the possible efficacy of pulse 
GC therapy in COVID-19 pneumonia complicated 
by a cytokine storm. The SHOKS-COVID score, the 
primary endpoint of the study, decreased significantly 
and more than in the control group. There was a 
significant improvement in the clinical condition 
as indicated by NEWS-2 score 8, oxygen saturation 
+9 %, body temperature back to normal values, and 
significant reduction in the need for oxygen therapy. 
This improvement was accompanied by a threefold 
decrease in the CRP levels, which characterized the 
rapid anti-inflammatory effect of high doses of GCs. As 
a result, the degree of pulmonary involvement did not 
change, unlike in the control group, where pneumonia 
progressed and the degree of pulmonary involvement 
significantly increased. The case report of patient I 
shows the progression of pulmonary involvement in the 
absence of anti-inflammatory therapy in the first period 
of  treatment (Figures 5.01, 5.02) and the resolution 
of the process after pulse GC therapy in the second 
period of observation (Figures 5.02, 5.03). To a certain 
extent, this is a remarkable clinical illustration of the 
comparative effect of control (no anti-inflammatory 
therapy, the first period) and pulse GC therapy (the 
second period) in the same patient. That was one of the 
first severe patients with COVID-19 in our hospital, and 
that experience taught us that the course of COVID-19 
pneumonia is extremely persistent and cannot be 
treated successfully without anti-inflammatory agents 
if markers of inflammation are increased. The findings 
demonstrated that pulse GC therapy could interrupt 
the cytokine storm. However, the results of the studies 
on COVID-19 did not confirm an improvement of 
the prognosis, but rather the opposite [27, 28]. Thus, 
recommendations were made to use anti-cytokine 
agents rather than GCs, which could also slow down 
the elimination of the virus during the treatment of 
COVID-19 [29, 30].
The second objective of the study was to assess 
the safety of high-doses pulse GC therapy in patients 
with COVID-19. We did not find adverse effects on 
cardiological parameters, including an increase in 
BP. There was also no increase in the glucose levels 
in the GC treatment group on average, although 
this parameter decreased significantly in the control 
group. The personified analysis showed that 6 of 17 
(35.3 %) patients had increased glucose levels of more 
than 9  mmol / l, which required ordering / enhancing 
hypoglycemic therapy. The changes in the D-dimer level 
posed the main problem. This parameter did not change 
in the control group and increased significantly (median 
up to 1.98 μg / ml) in the GC treatment group. Several 
studies demonstrated that the increased D-dimer levels 
of more than 2.0 μg / ml increased 51-fold the risk of VTE 
in patients with COVID-19 [31]. Other studies showed 
that even an increase in the D-dimer levels of more than 
1.0 μg / ml significantly increased by 18-fold the risk of 
thrombosis [32]. In our study, 4 patients had venous 
thrombosis (2 PEs) associated with an increase in the 
D-dimer levels of more than 10 μg / ml. Given the fact 
that thrombotic complications in COVID-19 are related 
to autoimmune inflammation, we analyzed the possible 
relationships. GCs are known to increase leukocyte and 
neutrophil counts [33]. In our study, neutrophil counts 
increased by 73 % (p<0.0001) in the GC treatment 
group and did not change in the control group.
The NLR statistically significantly increased by 2.5-fold 
with leukocyte counts remaining unchanged, and no 
changes were observed in the control group. The NLR 
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reflects the activation of chronic inflammation [34, 35], 
including autoimmune endothelial inflammation [36], and 
it characterizes the adverse course of COVID-19 [37, 38]. 
Therefore, we analyzed the correlation between changes 
in the NLR and the D-dimer levels during the treatment 
(Figure 7).
As can be seen in Figure 7, there was a direct, 
significant correlation between an increase in the 
D-dimer levels and the NLR in In all 34 investigated 
patients (r=0.47, p=0.005) and the GC treatment group 
(r=0.49, p=0.04). The was no such correlation in the 
control group. It should be especially noted that the 
NLR is not only a marker of inflammation but is also 
a predictor of VTE and PE [39, 40]. A study including 
180 patients with COVID-19 demonstrated a close 
statistically significant relationship between the NLR 
and the degree of pulmonary involvement according to 
CT findings [41]. Thus, despite the rapid reduction in 
the CRP levels and acute inflammation, as well as the 
clinical improvement in patients with COVID-19, the 
use of GCs increases neutrophil counts and the NLR. 
This results in a significantly higher risk of thrombosis 
as demonstrated by a significant increase in the D-dimer 
levels. The use of the NLR can predict both the severity 
of the COVID-19 course [42] and an unfavorable 
prognosis [43]. The risk of a lethal outcome in patients 
with coronavirus pneumonia increases 15-fold [44] 
with an increase in the NLR to maximum values 
(4.85–88.09), and the efficacy of GCs decreases with 
high NLR [45]. Therefore, it is necessary to take into 
account the NLR and the D-dimer levels and consider 
the enhancement of anticoagulant therapy when using 
high-dose pulse GC therapy as an anti-inflammatory 
treatment of the cytokine storm in patients with 
COVID-19.
Moreover, the recovery of lung airiness may be 
delayed [41, 46] if the NLR and chronic inflammation 
increase. This may extend the duration of treatment. 
Patients in the GC treatment group spent 8 days more 
in the hospital, although that may be partially explained 
by a more severe course of the disease. We order a 
course of the anti-inflammatory inflammasome inhibitor, 
colchicine, after the GC therapy to accelerate recovery, 
as is shown in our second case report. The clinical 
efficacy of this is currently being investigated (https://
clinicaltrials.gov / ct2 / show / NCT04403243).
Limitations of the study
A small number of patients was included in the 
study. The retrospective design of the study precluded 
randomization. There were intergroup differences in the 
baseline charac teristics.
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